Compare Hims and Hers Health Inc (HIMS) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Atlassian Corporation PLC — how do they compare? Hims and Hers Health Inc trades at $28.35 (market cap $6.89B), while Atlassian Corporation PLC trades at $203.05 (market cap $49.56B). The key difference: Atlassian Corporation PLC is far larger — about 7.2× Hims and Hers Health Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Atlassian Corporation PLC for 64 Days on average.
| HIMS | TEAM | |
|---|---|---|
Market Cap | $6.89B | $49.56B |
Volume | 5,446,628 | 1,747,462 |
Sector | Health | Technology |
52-Week High | $62.76 | $203.57 |
52-Week Low | $14.52 | $57.15 |
Typical Hold Time | 21 Days | 64 Days |
Enterprise Value | $7.60B | $49.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
Atlassian (TEAM) trades at $203.57, up 4.94% with strong technical momentum and bullish moving averages. The stock shows improving fundamentals with revenue growth from $5.22B in 2025 to projected $6.6B in 2026, though it remains unprofitable with a -0.82% net margin. Recent earnings beats and accelerating cloud/AI adoption drive positive sentiment, with analyst consensus strongly bullish at 70% buy ratings.
Outlook remains positive due to cloud migration progress and AI product adoption, but investors face valuation concerns with elevated P/S of 7.75 and EV/EBITDA of 233.57. Key risks include persistent profitability challenges and competitive pressures in enterprise software. Current price exceeds consensus target of $191.16, suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
